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Integrating multi-disciplinary discussion in clinical practice
Case presentation
A 68 year-old male was referred to our cli-
nic in order to investigate an abnormal chest 
radiography that was performed during work-up 
of an anemia with unknown onset. The patient 
reported shortness of breath over the last 4 
months (MMRC scale 2), dry cough, fatigue and 
an irregular fever up to 38°C two times/week. 
He is a former smoker (80 pack years) with no 
prior illnesses and without environmental or 
occupational hazards.
On physical examination, the patient had 
conjunctival paleness, diffuse crackles on au-
scultation of the lower lung fields bilaterally 
and palpable inguinal lymph nodes. Pulmonary 
function testing showed a mixed obstructive-re-
strictive defect and a moderately compromised 
diffusing capacity (FEV1 72%, FVC 81%, FEV1/ 
/FVC 0.74, TLC 71%, DLCO 52%). Blood tests 
showed hematocrit 37%, hemoglobin 12.3 g/dL, 
an erythrocyte sedimentation rate of 40 mm, and 
a C-reactive protein value of 6 mg/dL. An auto
-immunity panel was normal. A High-Resolution 
Computed Tomography (HRCT) scan showed 
a probable usual interstitial pneumonia (UIP) 
pattern with subpleural distribution consisting of 
reticulation and traction bronchiectasis, minimal 
ground-glass opacities, para-septal emphysema 
and one middle lobe nodule (Figure 1). A posi-
tron emission tomography (PET)-CT scan was 
performed to evaluate the nodule and to inve-
stigate enlarged lymph nodes in the abdomen. It 
demonstrated uptake in bones (spine, ribs, sca-
pula), mediastinum, a pulmonary nodule, liver, 
spleen, iliac and inguinal lymph nodes (Figure 1). 
Bronchoalveolar lavage was then performed and 
it showed increased cellularity (28 × 106 cells) 
with lymphocyte predominance (neutrophils 5%, 
lymphocytes 27%, eosinophils 1%, macrophages 
67%). Perls’ and CD1a stains were negative.
Multi-disciplinary discussion (MDD) con-
sisted of consultation between a radiologist, 
a pulmonologist, a pathologist and a hematologist. 
Together, they recognized a case of probable UIP 
with a non-diagnostic BAL demonstrating lym-
Figure 1. A. High resolution computed tomography scan of the lun-
gs showing subpleural lower lobes reticulation, ground-glass opa-
cities and bronciolectasis; B. Reticulation and a middle lobe nodule; 
C. Positron emission tomography-computed tomography scan sho-
wing pulmonary nodule and lymph nodes uptake as well as D. diffuse 
uptake in skeleton, spleen and lymph nodes
A B
C D
Ilias C. Papanikolaou et al., Integrating multi-disciplinary discussion in clinical practice
275www.journals.viamedica.pl
phocytosis in a clinical context not typical for 
idiopathic pulmonary fibrosis (IPF). In addition, 
there were many systemic symptoms and findings 
suggestive of possible alternative diagnoses. 
Histological diagnosis was deemed necessary; 
a decision was made to pursue a surgical biopsy 
from the most easily assessible site. Inguinal 
lymph node pathology demonstrated numerous 
Langerhans cells with characteristic grooved 
nuclei which stained immunohistochemically 
positive for langerin and CD1a (Figure 2). MDD 
considered the findings and a diagnosis of mul-
tisystemic Langerhans cell histiocytosis (LCH) 
was established.
Discussion
Our patient’s HRCT pattern was classified 
as having a probable UIP pattern (reticulation, 
subpleural distribution, without honeycombing) 
based on the latest ATS/ERS/JRS/ALAT guidelines 
for the diagnosis of IPF [1]. Although Langerhans 
cell histiocytosis is considered among the etio-
logies of the alternative diagnosis HRCT pattern, 
this patient’s scan had no cysts, no profound 
ground-glass opacities and only one nodule. The 
probable UIP pattern, however, needs to be inve-
stigated further. The same guidelines provide con-
ditional recommendation for an MDD procedure 
in order to select further diagnostic procedures 
in the case of a probable UIP pattern, indicating 
BAL cellular analysis and surgical lung biopsy as 
potential next steps.
Fleishner’s society white paper on IPF 
diagnostic criteria identifies the presence of 
systemic features (like in this case) as a key 
checklist component for a diagnosis alternative 
to IPF [2]. Moreover, the authors conclude that 
MDD is necessary when the clinical context or 
the HRCT pattern is/are indeterminate for IPF. 
The clinical context in the case we present was 
clearly indeterminate considering the systemic 
features and multi-organ involvement. Accor-
ding to the authors, the outcome of the MDD 
will lead to a decision on whether to perform 
additional investigations, BAL or surgical lung 
biopsy and to integrate, after a biopsy is per-
formed, the clinical, imaging and pathological 
features. Based on these conclusions, MDD may 
provide guidance as to what is the most suitable 
procedure.  
A clinical practice guideline by the American 
Thoracic Society recommends performing BAL 
in patients that lack a confident UIP pattern on 
HRCT and who can tolerate the procedure [3]. 
BAL may be diagnostic in rare diseases and may 
narrow the differential diagnosis by the respective 
cellular profile (lymphocytic, neutrophilic or eo-
sinophilic). In our case, BAL was CD1a negative 
and demonstrated lymphocytosis. Therefore, the 
need for a surgical diagnosis was not obviated. 
BAL may precede surgical lung biopsy as a less 
interventional procedure when the differential 
diagnosis includes rare diseases or diseases with 
a predominant lymphocytic or eosinophilic cel-
lular profile as an adjunct to diagnosis. 
Langerhans cell histiocytosis (LCH), as clas-
sified by the World Health Organization, is a rare 
dendritic cell disorder [4]. Acute disseminated 
multisystem disease is commonly seen in child-
ren less than three years old [5]. Our patient was 
started on prednisolone plus vinblastine, with 
partial response. Of note, the pulmonary nodule 
completely disappeared after the initial regimen 
and did not re-appear. The prognosis was poor 
and our patient passed away 13 months after 
initial diagnosis. 
In the era of modern anti-fibrotic medica-
tions approved for use in IPF, we present a case 
of probable UIP other than IPF. We would like to 
point out that the pulmonologist should always 
rigorously investigate extra-pulmonary signs 
and symptoms when present, and not restrict 
his differential diagnosis to solely lung-oriented 
diffuse pulmonary diseases. Provisional IPF dia-
gnosis that allows to avoid invasive procedures 
like surgical lung biopsy is useful but only when 
used in the appropriate clinical setting.   
Figure 2. A. Lymph node involved in Langerhans cell histiocytosis 
exhibited partial effacement of normal nodal architecture (H&E, magni-
ficationX40); B. Lymph node biopsy showed the presence of numerous 
Langerhans cells with the characteristic grooved nuclei (H&E, magni-
ficationX400), (inset: magnificationX600). No nuclear atypia, necrosis 
or increased number of mitotic figures were noted; C. Langerhans 
cells stained immunohistochemically positive for CD1a and D. langerin 
(CD207) (DAB, magnificationX100)
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